Free Trial

Vivani Medical (VANI) Financials

Vivani Medical logo
$1.01 +0.00 (+0.50%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Vivani Medical

Annual Income Statements for Vivani Medical

This table shows Vivani Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-20 -33 -29 -35 -34 -16 -13 -14 -26 -23 -27
Consolidated Net Income / (Loss)
-20 -33 -29 -35 -34 -15 -13 -14 -26 -23 -27
Net Income / (Loss) Continuing Operations
-20 -33 -29 -35 -34 -16 -13 -14 -26 -23 -27
Total Pre-Tax Income
-20 -33 -29 -35 -34 -16 -13 -21 -27 -23 -27
Total Operating Income
-20 -33 -29 -35 -34 -15 -13 -21 -27 -25 -28
Total Gross Profit
3.66 -6.09 2.85 2.01 1.23 0.50 0.00 0.00 0.00 0.00 0.00
Total Revenue
8.95 3.99 7.96 6.90 3.38 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
5.29 10 5.12 4.89 2.15 0.50 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
24 27 31 37 35 15 13 21 27 25 28
Selling, General & Admin Expense
8.22 10 11 11 9.23 5.94 2.32 7.07 10.00 8.93 9.43
Research & Development Expense
3.04 5.35 7.89 10 13 4.84 11 14 17 16 18
Total Other Income / (Expense), net
0.00 0.03 0.09 0.09 0.36 0.02 0.55 0.00 0.00 1.19 0.95
Other Income / (Expense), net
- - - - - - - - - 1.19 0.95
Basic Earnings per Share
($0.56) ($0.84) ($0.53) ($4.23) ($2.28) ($0.72) - ($0.36) ($0.50) ($0.43) ($0.43)
Weighted Average Basic Shares Outstanding
35.64M 39.55M 54.15M 8.30M 14.71M 20.58M 32.82M 38.24M 50.85M 54.98M 62.39M
Diluted Earnings per Share
($0.56) ($0.84) ($0.53) ($4.23) ($2.28) ($0.72) - ($0.36) ($0.50) ($0.43) ($0.43)
Weighted Average Diluted Shares Outstanding
35.64M 39.55M 54.15M 8.30M 14.71M 20.58M 32.82M 38.24M 50.85M 54.98M 62.39M
Weighted Average Basic & Diluted Shares Outstanding
35.64M 39.55M 54.15M 8.30M 14.71M 20.58M 32.82M 38.24M 50.85M 59.24M 84.65M

Quarterly Income Statements for Vivani Medical

This table shows Vivani Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-6.04 -5.36 -6.04 -6.05 -6.30 -7.14 -6.53 -6.63 -6.78 -6.37 -7.25
Consolidated Net Income / (Loss)
-6.04 -5.36 -6.04 -6.05 -6.30 -7.14 -6.53 -6.63 -6.78 -6.37 -7.25
Net Income / (Loss) Continuing Operations
-6.04 -5.36 -6.04 -6.05 -6.30 -7.14 -6.53 -6.63 -6.82 -6.37 -7.25
Total Pre-Tax Income
-6.04 -5.68 -6.31 -5.46 -6.30 -7.46 -6.73 -5.87 -6.82 -6.37 -7.53
Total Operating Income
-6.23 -5.68 -6.31 -6.46 -6.56 -7.46 -6.73 -6.81 -6.82 -6.87 -7.53
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
6.23 5.68 6.31 6.46 6.56 7.46 6.73 6.81 6.78 6.87 7.53
Selling, General & Admin Expense
2.50 2.17 2.11 2.16 2.34 2.70 2.21 2.18 2.43 2.42 2.51
Research & Development Expense
3.73 3.51 4.20 4.30 4.22 4.76 4.52 4.63 4.39 4.46 5.02
Total Other Income / (Expense), net
0.19 0.00 0.00 1.00 0.26 0.00 0.00 0.95 0.00 0.50 0.00
Other Gains / (Losses), net
- 0.33 0.27 - - 0.32 0.20 - - - 0.28
Basic Earnings per Share
($0.12) ($0.10) ($0.11) ($0.10) ($0.11) ($0.12) ($0.11) ($0.09) ($0.08) ($0.07) ($0.08)
Weighted Average Basic Shares Outstanding
52.20M 55.02M 55.25M 54.98M 59.24M 59.24M 59.71M 62.39M 81.27M 87.09M 90.12M
Diluted Earnings per Share
($0.12) ($0.10) ($0.11) ($0.10) ($0.11) ($0.12) ($0.11) ($0.09) ($0.08) ($0.07) ($0.08)
Weighted Average Diluted Shares Outstanding
52.20M 55.02M 55.25M 54.98M 59.24M 59.24M 59.71M 62.39M 81.27M 87.09M 90.12M
Weighted Average Basic & Diluted Shares Outstanding
52.20M 55.26M 59.23M 59.24M 59.24M 59.24M 72.95M 84.65M 86.24M 90.20M 90.20M

Annual Cash Flow Statements for Vivani Medical

This table details how cash moves in and out of Vivani Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-0.38 -5.09 -3.04 -3.37 6.86 -8.15 0.10 44 -24 -2.30 -2.12
Net Cash From Operating Activities
-21 -25 -24 -30 -28 -17 -11 -19 -24 -21 -24
Net Cash From Continuing Operating Activities
-21 -25 -24 -30 -28 -17 -11 -19 -24 -21 -24
Net Income / (Loss) Continuing Operations
-20 -33 -29 -35 -34 -15 -13 -14 -26 -23 -27
Consolidated Net Income / (Loss)
-20 -33 -29 -35 -34 -15 -13 -14 -26 -23 -27
Depreciation Expense
0.34 0.43 0.46 0.44 0.40 0.16 0.35 0.38 0.36 0.40 0.42
Non-Cash Adjustments To Reconcile Net Income
3.14 8.41 0.91 4.70 5.30 2.00 1.04 -5.62 1.99 1.95 1.64
Changes in Operating Assets and Liabilities, net
-4.00 -0.73 3.21 0.15 0.26 -4.10 0.44 0.34 -1.29 0.35 0.23
Net Cash From Investing Activities
18 -0.49 -0.27 -0.16 -0.49 0.07 -0.57 -0.34 -0.89 -0.56 -1.17
Net Cash From Continuing Investing Activities
18 -0.49 -0.27 -0.16 -0.49 0.07 -0.57 -0.34 -0.89 -0.56 -1.17
Purchase of Property, Plant & Equipment
-0.76 -0.49 -0.27 -0.16 -0.49 -0.33 -0.57 -0.34 -0.89 -0.56 -1.17
Net Cash From Financing Activities
2.76 20 21 27 35 8.60 12 63 0.13 19 23
Net Cash From Continuing Financing Activities
2.76 20 21 27 35 8.60 12 63 0.13 19 23
Issuance of Common Equity
0.00 19 21 26 35 6.68 12 0.02 0.00 5.13 23
Other Financing Activities, net
2.76 0.97 0.40 0.67 0.48 0.00 0.00 55 0.13 0.24 0.01
Effect of Exchange Rate Changes
-0.11 0.02 0.01 0.00 -0.01 0.01 0.00 -0.00 0.00 -0.01 0.10
Cash Income Taxes Paid
- - - - - 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Vivani Medical

This table details how cash moves in and out of Vivani Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
8.99 -4.73 -5.27 -1.29 -5.34 -6.21 -4.17 14 3.52 -0.30 -5.30
Net Cash From Operating Activities
-4.51 -4.80 -5.66 -5.81 -5.16 -6.09 -6.35 -6.72 -6.20 -6.04 -6.39
Net Cash From Continuing Operating Activities
-4.51 -4.80 -5.66 -5.81 -5.16 -6.09 -6.35 -6.72 -6.20 -6.04 -6.39
Net Income / (Loss) Continuing Operations
-6.04 -5.36 -6.04 -6.05 -6.30 -7.14 -6.53 -6.63 -6.78 -6.37 -7.25
Consolidated Net Income / (Loss)
-6.04 -5.36 -6.04 -6.05 -6.30 -7.14 -6.53 -6.63 -6.78 -6.37 -7.25
Depreciation Expense
0.10 0.10 0.11 0.09 0.10 0.10 0.11 0.12 0.13 0.13 0.13
Non-Cash Adjustments To Reconcile Net Income
0.35 0.42 0.69 0.49 0.41 0.44 0.32 0.47 0.35 0.01 0.39
Changes in Operating Assets and Liabilities, net
0.99 -0.04 -0.27 -0.34 0.63 0.51 -0.24 -0.67 0.11 0.20 0.34
Net Cash From Financing Activities
14 0.11 0.43 4.83 -0.17 -0.10 2.95 21 9.71 5.83 1.09
Net Cash From Continuing Financing Activities
14 0.11 0.43 4.83 -0.17 -0.10 2.95 21 9.71 5.83 1.09
Issuance of Common Equity
0.00 0.11 0.05 4.97 0.00 0.03 2.57 21 9.82 5.94 1.00
Other Financing Activities, net
0.00 - - -0.14 -0.14 -0.12 0.38 -0.11 -0.11 -0.11 0.09

Annual Balance Sheets for Vivani Medical

This table presents Vivani Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
28 17 14 11 17 4.46 5.45 51 46 42 39
Total Current Assets
27 15 13 9.62 13 4.27 2.47 48 23 20 18
Cash & Equivalents
0.24 0.54 7.84 4.47 11 3.18 2.18 45 21 18 16
Prepaid Expenses
1.09 0.72 0.80 1.40 0.30 1.09 0.29 2.45 2.41 1.84 1.01
Other Current Assets
16 10 - - - - - - 0.00 0.25 0.65
Plant, Property, & Equipment, net
1.43 1.49 1.30 1.03 1.12 0.17 1.17 1.18 1.73 1.69 2.88
Total Noncurrent Assets
0.05 0.04 0.03 0.04 2.37 0.02 1.81 2.42 21 19 19
Other Noncurrent Operating Assets
0.05 0.04 0.03 0.04 2.37 0.02 1.81 2.42 20 19 19
Total Liabilities & Shareholders' Equity
28 17 14 11 17 4.46 5.45 51 46 42 39
Total Liabilities
7.98 5.66 6.62 7.60 9.32 5.13 2.99 6.82 25 24 24
Total Current Liabilities
7.98 5.66 6.62 7.60 6.96 5.13 2.09 6.82 5.72 5.99 6.60
Accounts Payable
0.71 1.16 0.75 1.31 1.09 0.49 0.28 1.18 0.54 0.82 1.03
Accrued Expenses
2.68 2.72 3.20 3.44 2.60 2.27 0.90 2.36 1.73 1.80 1.74
Current Employee Benefit Liabilities
2.07 1.60 2.61 2.69 2.70 0.17 0.00 0.66 0.40 0.34 0.37
Other Current Liabilities
- - 0.05 0.17 0.57 0.00 0.91 2.63 3.06 3.02 3.47
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 2.37 0.00 0.90 0.00 19 18 17
Other Noncurrent Operating Liabilities
- - - - 2.37 - 0.90 0.00 19 18 17
Commitments & Contingencies
- 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
20 11 7.88 3.08 7.28 -0.67 2.47 44 21 18 16
Total Preferred & Common Equity
20 11 7.88 3.08 7.28 -0.67 2.47 44 21 18 16
Total Common Equity
20 11 7.88 3.08 7.28 -0.67 2.47 44 21 18 16
Common Stock
193 217 243 273 313 319 61 117 119 139 164
Retained Earnings
-173 -206 -234 -269 -305 -320 -59 -73 -98 -122 -149
Accumulated Other Comprehensive Income / (Loss)
-0.58 -0.61 -0.57 -0.58 -0.56 -0.45 0.00 0.04 0.14 0.05 0.03

Quarterly Balance Sheets for Vivani Medical

This table presents Vivani Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
53 54 48 43 35 29 25 42 42 35
Total Current Assets
31 32 26 21 15 8.72 4.18 22 22 16
Cash & Equivalents
25 30 25 20 13 6.79 2.63 20 20 15
Prepaid Expenses
5.86 1.85 1.42 1.75 1.67 1.43 0.88 1.10 1.03 0.94
Other Current Assets
- - - - - - 0.66 - - 0.31
Plant, Property, & Equipment, net
1.13 1.69 1.71 1.64 1.61 1.58 2.73 2.75 2.85 2.76
Total Noncurrent Assets
22 21 20 20 19 19 18 18 17 17
Other Noncurrent Operating Assets
22 21 20 20 19 19 18 18 17 17
Total Liabilities & Shareholders' Equity
53 54 48 43 35 29 25 42 42 35
Total Liabilities
27 25 24 25 24 24 24 23 23 22
Total Current Liabilities
7.43 6.14 5.78 6.27 6.20 6.72 6.83 6.78 6.66 6.59
Accounts Payable
1.89 0.57 0.65 0.82 1.00 1.76 1.43 1.47 1.20 1.21
Accrued Expenses
1.82 1.95 1.66 2.02 1.86 1.59 1.98 1.50 1.63 1.36
Current Employee Benefit Liabilities
0.68 0.51 0.38 0.37 0.35 0.36 0.36 0.35 0.32 0.32
Other Current Liabilities
3.05 3.11 3.10 3.06 2.99 3.01 3.06 3.46 3.52 3.70
Total Noncurrent Liabilities
20 19 19 18 18 17 17 16 16 16
Other Noncurrent Operating Liabilities
- 19 19 18 18 17 17 16 16 16
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
26 29 24 18 12 4.91 1.31 19 19 13
Total Preferred & Common Equity
26 29 24 18 12 4.91 1.31 19 19 13
Total Common Equity
26 29 24 18 12 4.91 1.31 19 19 13
Common Stock
119 133 134 134 140 140 143 174 181 182
Retained Earnings
-92 -104 -110 -116 -128 -135 -142 -155 -162 -169
Accumulated Other Comprehensive Income / (Loss)
0.05 0.09 0.06 0.09 0.04 0.08 0.14 0.03 0.03 0.03

Annual Metrics And Ratios for Vivani Medical

This table displays calculated financial ratios and metrics derived from Vivani Medical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
35,851,400.00 42,246,954.00 56,806,352.00 72,780,549.00 124,598,198.00 23,118,233.00 39,409,176.00 50,735,770.00 51,025,060.00 59,234,689.00 72,952,235.00
DEI Adjusted Shares Outstanding
1,493,808.00 1,760,290.00 2,366,931.00 3,032,523.00 5,191,592.00 7,706,078.00 13,136,392.00 50,735,770.00 51,025,060.00 59,234,689.00 72,952,235.00
DEI Earnings Per Adjusted Shares Outstanding
-13.40 -18.85 -12.05 -11.57 -6.47 -2.06 -0.97 -0.27 -0.50 -0.40 -0.36
Growth Metrics
- - - - - - - - - - -
Revenue Growth
163.39% -55.47% 99.85% -13.41% -51.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
5.93% -66.28% 14.11% -23.42% 3.42% 56.10% 11.91% -60.73% -23.22% 10.19% -13.42%
EBIT Growth
39.74% -65.66% 13.85% -22.97% 3.48% 56.13% 10.56% -59.43% -26.95% 12.90% -13.30%
NOPAT Growth
5.59% -65.66% 13.85% -22.97% 3.48% 56.13% 10.56% -59.43% -26.95% 8.49% -11.67%
Net Income Growth
43.13% -65.75% 14.05% -23.07% 4.28% 55.70% 14.16% -8.74% -84.69% 8.44% -13.30%
EPS Growth
60.28% -50.00% 36.90% -23.07% 4.28% 68.42% 0.00% 0.00% -38.89% 14.00% 0.00%
Operating Cash Flow Growth
-20.23% -22.00% 4.48% -24.48% 7.32% 39.11% 34.90% -71.56% -26.15% 12.29% -17.00%
Free Cash Flow Firm Growth
-129.16% 59.39% 31.61% -145.19% 9.02% 39.20% 12.22% -22.66% -33.29% 3.53% -9.94%
Invested Capital Growth
2,002,500.00% -47.02% -99.59% -3,325.58% -192.14% 59.30% 117.40% -367.60% -60.29% 39.72% 32.35%
Revenue Q/Q Growth
39.62% -45.64% 42.98% -16.29% -27.32% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-32.49% 0.20% 9.46% -4.36% 2.18% 31.47% -34.91% -17.30% 8.79% 3.91% 2.32%
EBIT Q/Q Growth
-32.07% 0.15% 9.35% -4.28% 2.16% 31.51% -34.60% -17.11% 5.56% 3.88% 2.19%
NOPAT Q/Q Growth
-32.07% 0.15% 9.35% -4.28% 2.16% 31.51% -34.60% -17.11% 5.56% -0.99% -1.29%
Net Income Q/Q Growth
13.60% 0.17% 9.41% -4.31% 2.86% 30.65% -28.77% -29.21% 4.68% -0.10% -2.24%
EPS Q/Q Growth
38.46% -13.51% 3.64% -4.31% 2.86% 22.58% 0.00% 99.87% 5.66% -2.38% 2.27%
Operating Cash Flow Q/Q Growth
-30.49% -4.67% 1.25% -3.53% 1.23% 26.07% -15.94% -13.56% 6.77% -12.63% -3.87%
Free Cash Flow Firm Q/Q Growth
0.00% 66.07% 32.92% -127.36% 10.67% 14.91% -75.84% 6.87% 55.45% -436.72% -2.58%
Invested Capital Q/Q Growth
606.32% -47.80% -99.65% -28.43% -131.68% 12.98% 111.86% -172.34% -105.84% 43.53% 61.94%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
40.86% -152.85% 35.75% 29.12% 36.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-220.25% -822.53% -353.49% -503.84% -993.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-223.99% -833.38% -359.23% -510.15% -1,004.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-223.99% -833.38% -359.23% -510.15% -1,004.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-223.66% -832.60% -358.06% -508.90% -994.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
99.87% 100.00% 100.00% 100.00% 100.00% 93.70% 100.00% 65.39% 95.13% 100.00% 100.00%
Interest Burden Percent
99.99% 99.91% 99.67% 99.76% 98.93% 106.61% 95.87% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-140.17% -151.78% -376.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-105.83% 2,401.44% -173.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
67.22% -59.48% 76.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-72.95% -211.26% -299.70% -640.05% -648.56% -450.70% -1,424.76% -59.39% -78.85% -122.42% -159.62%
Cash Return on Invested Capital (CROIC)
-170.09% -90.31% -177.62% 0.00% 0.00% 0.00% -3,924.08% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-56.22% -147.42% -182.76% -279.44% -248.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-56.14% -147.28% -182.17% -278.76% -246.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-72.95% -211.26% -299.70% -640.05% -648.56% -450.70% -1,424.76% -59.39% -78.85% -122.42% -159.62%
Return on Equity Simple (ROE_SIMPLE)
-98.79% -297.62% -361.79% -1,137.94% -461.75% 2,214.29% -518.17% -31.35% -123.56% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-14 -23 -20 -25 -24 -10 -9.33 -15 -19 -17 -19
NOPAT Margin
-156.79% -583.36% -251.46% -357.11% -703.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-34.34% -2,553.21% -202.67% -170.07% -124.37% -72.38% -218.50% 4.15% -20.21% -30.80% -42.33%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -90.92% -98.09% -122.63%
Cost of Revenue to Revenue
59.14% 252.85% 64.25% 70.88% 63.69% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
91.88% 252.95% 137.27% 155.05% 273.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
33.92% 134.18% 99.11% 145.08% 388.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
264.85% 680.53% 394.98% 539.27% 1,041.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-20 -33 -29 -35 -34 -15 -13 -21 -27 -23 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-20 -33 -28 -35 -34 -15 -13 -21 -26 -23 -26
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
10.42 7.47 13.77 20.90 12.71 0.00 26.06 0.97 2.51 3.90 5.70
Price to Tangible Book Value (P/TBV)
10.42 7.47 13.77 20.90 12.71 0.00 26.06 0.97 2.51 3.90 5.70
Price to Revenue (P/Rev)
23.59 20.88 13.62 9.35 27.36 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
10.53 7.79 2,340.96 0.00 0.00 0.00 216.23 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
23.57 20.75 12.64 8.70 24.01 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 -3.27 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.64 -0.02 -0.44 -1.12 -1.53 -1.86 -1.76 -1.01 -1.03 -1.05 -1.04
Leverage Ratio
1.30 1.43 1.65 2.30 2.63 3.19 5.53 1.21 1.49 2.28 2.43
Compound Leverage Factor
1.30 1.43 1.64 2.29 2.61 3.40 5.30 1.21 1.49 2.28 2.43
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 143.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 143.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% -43.98% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 -0.15 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 -0.21 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
6.09 -13.92 -18.21 -40.22 -25.86 -106.54 -10.20 1.38 -3.25 -3.83 -4.89
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.35 2.70 1.99 1.27 1.88 0.83 1.18 6.97 4.03 3.42 2.71
Quick Ratio
0.22 0.14 1.46 0.65 1.69 0.62 1.04 6.61 3.61 3.07 2.46
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-34 -14 -9.46 -23 -21 -13 -11 -14 -18 -18 -20
Operating Cash Flow to CapEx
-2,696.72% -5,116.33% -9,036.60% -18,288.34% -5,604.26% -5,097.58% -1,914.51% -5,558.28% -2,671.82% -3,738.49% -2,073.32%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.25 0.18 0.51 0.55 0.25 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
8.10 4.49 7.57 5.91 7.05 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.76 1.73 1.67 1.64 1.01 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
7.35 2.73 5.71 5.93 3.15 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
8.66 10.80 5.36 4.75 1.79 0.63 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
45.04 81.29 48.24 61.79 51.80 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
480.33 210.56 218.13 222.15 362.88 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
42.17 33.80 68.05 76.80 203.36 576.34 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
483.21 258.05 198.32 207.15 211.31 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
20 11 0.04 -1.39 -4.05 -1.65 0.29 -0.77 -1.23 -0.74 -0.50
Invested Capital Turnover
0.89 0.26 1.50 -10.26 -1.24 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
20 -9.42 -11 -1.43 -2.67 2.40 1.94 -1.06 -0.46 0.49 0.24
Enterprise Value (EV)
211 83 101 60 81 42 62 -1.97 31 50 73
Market Capitalization
211 83 109 64 92 43 64 43 52 69 90
Book Value per Share
$0.57 $0.26 $0.14 $0.04 $0.06 ($0.03) $0.06 $0.87 $0.41 $0.30 $0.22
Tangible Book Value per Share
$0.57 $0.26 $0.14 $0.04 $0.06 ($0.03) $0.06 $0.87 $0.41 $0.30 $0.22
Total Capital
20 11 7.88 3.08 7.28 1.53 2.47 44 21 18 16
Total Debt
0.00 0.00 0.00 0.00 0.00 2.20 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-0.24 -0.54 -7.84 -4.47 -11 -0.98 -2.18 -45 -21 -18 -16
Capital Expenditures (CapEx)
0.76 0.49 0.27 0.16 0.49 0.33 0.57 0.34 0.89 0.56 1.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)
19 9.08 -1.29 -2.45 -5.18 -1.84 -1.80 -4.37 -3.32 -3.90 -4.94
Debt-free Net Working Capital (DFNWC)
19 9.62 6.55 2.02 6.15 1.34 0.38 41 17 14 11
Net Working Capital (NWC)
19 9.62 6.55 2.02 6.15 -0.86 0.38 41 17 14 11
Net Nonoperating Expense (NNE)
5.99 9.93 8.49 10 9.82 4.45 3.45 -0.98 6.78 6.21 7.32
Net Nonoperating Obligations (NNO)
-0.24 -0.54 -7.84 -4.47 -11 -0.98 -2.18 -45 -22 -18 -16
Total Depreciation and Amortization (D&A)
0.34 0.43 0.46 0.44 0.40 0.16 0.35 0.38 1.26 0.40 0.42
Debt-free, Cash-free Net Working Capital to Revenue
207.18% 227.88% -16.19% -35.51% -153.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
209.85% 241.41% 82.25% 29.32% 182.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
209.85% 241.41% 82.25% 29.32% 182.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($13.44) ($20.16) ($12.72) ($12.72) ($6.84) ($2.16) ($0.81) $0.00 ($0.50) ($0.43) ($0.43)
Adjusted Weighted Average Basic Shares Outstanding
1.50M 2.35M 2.49M 5.17M 5.22M 7.75M 15.70M 58.42M 54.98M 54.98M 62.39M
Adjusted Diluted Earnings per Share
($13.44) ($20.16) ($12.72) ($12.72) ($6.84) ($2.16) ($0.81) $0.00 ($0.50) ($0.43) ($0.43)
Adjusted Weighted Average Diluted Shares Outstanding
1.50M 2.35M 2.49M 5.17M 5.22M 7.75M 15.70M 58.42M 54.98M 54.98M 62.39M
Adjusted Basic & Diluted Earnings per Share
($13.44) ($20.16) ($12.72) ($12.72) ($6.84) ($2.16) ($0.81) $0.00 ($0.50) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.48M 1.65M 2.26M 2.77M 4.90M 6.86M 10.94M 38.24K 50.85M 59.24M 84.65M
Normalized Net Operating Profit after Tax (NOPAT)
-14 -23 -20 -24 -21 -8.87 -9.33 -15 -19 -17 -19
Normalized NOPAT Margin
-156.79% -583.36% -251.46% -351.47% -633.85% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-223.97% -832.60% -358.06% -508.90% -994.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% -1.89% 0.00% 0.00% 0.00% 58.28% 0.00%

Quarterly Metrics And Ratios for Vivani Medical

This table displays calculated financial ratios and metrics derived from Vivani Medical's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
54,978,000.00 54,978,465.00 55,255,856.00 59,234,689.00 59,242,903.00 59,243,903.00 59,243,903.00 72,952,235.00 84,647,803.00 86,235,104.00 90,203,356.00
DEI Adjusted Shares Outstanding
54,978,000.00 54,978,465.00 55,255,856.00 59,234,689.00 59,242,903.00 59,243,903.00 59,243,903.00 72,952,235.00 84,647,803.00 86,235,104.00 90,203,356.00
DEI Earnings Per Adjusted Shares Outstanding
-0.11 -0.10 -0.11 -0.10 -0.11 -0.12 -0.11 -0.09 -0.08 -0.07 -0.08
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
9.78% 20.44% 2.75% -5.41% -5.84% -33.62% -6.83% -5.12% -7.85% 15.19% -11.83%
EBIT Growth
8.51% 18.88% 11.69% -3.91% -4.36% -31.35% -6.59% -5.45% -8.17% 14.63% -12.00%
NOPAT Growth
5.67% 18.88% 11.69% -3.91% -5.30% -31.35% -6.59% -5.45% -3.97% 7.88% -12.00%
Net Income Growth
4.42% 17.93% 10.93% -0.40% -4.36% -33.38% -8.09% -9.64% -7.58% 10.83% -11.03%
EPS Growth
0.00% 23.08% 15.38% 16.67% 8.33% -20.00% 0.00% 10.00% 27.27% 41.67% 27.27%
Operating Cash Flow Growth
35.23% 13.50% 26.50% -66.96% -14.43% -26.79% -12.19% -15.61% -20.01% 0.85% -0.61%
Free Cash Flow Firm Growth
-285.59% 193.96% 168.18% -28.85% -32.57% -125.85% -126.18% 0.05% -32.53% -30.09% -10.97%
Invested Capital Growth
-417.97% -105.47% -106.24% 39.72% -47.55% -72.05% -0.38% 32.35% 52.02% 50.80% -4.09%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
3.08% 5.97% -12.51% -2.81% 2.68% -14.02% 10.05% -1.16% 0.15% 6.65% -18.60%
EBIT Q/Q Growth
2.86% 5.93% -11.05% -2.39% 2.45% -13.80% 9.88% -1.29% -0.07% 6.56% -18.24%
NOPAT Q/Q Growth
-0.16% 8.77% -11.05% -2.39% -1.50% -13.80% 9.88% -1.29% -0.07% -0.84% -9.57%
Net Income Q/Q Growth
-0.22% 11.31% -12.79% -0.15% -4.17% -13.36% 8.59% -1.58% -2.22% 6.05% -13.81%
EPS Q/Q Growth
0.00% 16.67% -10.00% 9.09% -10.00% -9.09% 8.33% 18.18% 11.11% 12.50% -14.29%
Operating Cash Flow Q/Q Growth
-29.62% -6.41% -17.91% -2.67% 11.17% -17.90% -4.34% -5.79% 7.78% 2.60% -5.88%
Free Cash Flow Firm Q/Q Growth
19.62% 648.75% 4.72% -127.90% 17.30% -7.01% -6.05% -6.51% -9.65% -5.04% 9.54%
Invested Capital Q/Q Growth
23.80% -16.74% -20.00% 43.53% -86.52% -36.13% 29.99% 61.94% -32.27% -39.61% -48.11%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 94.28% 95.75% 110.87% 100.00% 95.74% 97.10% 113.09% 99.46% 100.00% 96.26%
Interest Burden Percent
100.00% 100.00% 100.00% 84.47% 100.00% 100.00% 100.00% 86.10% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-75.65% -86.10% -105.35% -122.42% -117.76% -177.75% -265.02% -159.62% -176.41% -220.40% -372.18%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-75.65% -86.10% -105.35% -122.42% -117.76% -177.75% -265.02% -159.62% -176.41% -220.40% -372.18%
Return on Equity Simple (ROE_SIMPLE)
-88.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-4.36 -3.98 -4.42 -4.52 -4.59 -5.22 -4.71 -4.77 -4.77 -4.81 -5.27
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-4.96% -7.40% -13.11% -7.57% -8.03% -12.11% -16.36% -10.78% -12.26% -11.68% -22.97%
Return On Investment Capital (ROIC_SIMPLE)
-15.18% -16.69% -24.09% -25.68% -39.49% -106.38% -359.63% -30.31% -25.00% -25.37% -39.89%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-6.04 -5.68 -6.31 -6.46 -6.30 -7.46 -6.73 -6.81 -6.82 -6.37 -7.53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-5.86 -5.51 -6.20 -6.37 -6.20 -7.36 -6.62 -6.70 -6.69 -6.24 -7.40
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.54 2.91 3.53 3.90 5.35 15.57 63.82 5.70 4.44 5.64 8.46
Price to Tangible Book Value (P/TBV)
3.54 2.91 3.53 3.90 5.35 15.57 63.82 5.70 4.44 5.64 8.46
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 12.89 8.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.01 -0.66 -0.56 -1.05 -1.06 -1.10 -1.13 -1.04 -1.07 -1.12 -1.19
Leverage Ratio
1.47 1.92 2.16 2.28 2.21 2.68 3.46 2.43 2.53 2.95 4.15
Compound Leverage Factor
1.47 1.92 2.16 1.92 2.21 2.68 3.46 2.09 2.53 2.95 4.15
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-0.09 -1.36 -2.26 -2.48 -3.79 -5.41 -6.83 -3.23 -3.06 -2.68 -4.05
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.13 4.55 3.41 3.42 2.40 1.30 0.61 2.71 3.18 3.25 2.40
Quick Ratio
4.83 4.31 3.13 3.07 2.10 1.01 0.38 2.46 2.92 2.99 2.22
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-3.13 17 18 -5.01 -4.14 -4.43 -4.70 -5.01 -5.49 -5.77 -5.22
Operating Cash Flow to CapEx
-2,479.12% -12,975.68% -13,807.32% -1,963.51% -103,260.00% -8,573.24% -771.69% -2,452.19% -206,533.33% -6,095.96% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-0.94 -1.10 -1.31 -0.74 -1.38 -1.88 -1.32 -0.50 -0.66 -0.93 -1.37
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-1.23 -21 -22 0.49 -0.45 -0.79 -0.01 0.24 0.72 0.96 -0.05
Enterprise Value (EV)
72 44 45 50 49 70 81 73 65 87 97
Market Capitalization
102 69 65 69 62 76 84 90 85 107 112
Book Value per Share
$0.52 $0.43 $0.33 $0.30 $0.20 $0.08 $0.02 $0.22 $0.23 $0.22 $0.15
Tangible Book Value per Share
$0.52 $0.43 $0.33 $0.30 $0.20 $0.08 $0.02 $0.22 $0.23 $0.22 $0.15
Total Capital
29 24 18 18 12 4.91 1.31 16 19 19 13
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-30 -25 -20 -18 -13 -6.79 -2.63 -16 -20 -20 -15
Capital Expenditures (CapEx)
0.18 0.04 0.04 0.30 0.01 0.07 0.82 0.27 0.00 0.10 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.28 -4.37 -4.52 -3.90 -4.36 -4.80 -5.28 -4.94 -4.98 -4.92 -5.34
Debt-free Net Working Capital (DFNWC)
25 21 15 14 8.65 2.00 -2.66 11 15 15 9.25
Net Working Capital (NWC)
25 21 15 14 8.65 2.00 -2.66 11 15 15 9.25
Net Nonoperating Expense (NNE)
1.68 1.38 1.62 1.53 1.71 1.92 1.82 1.86 2.01 1.56 1.98
Net Nonoperating Obligations (NNO)
-30 -25 -20 -18 -13 -6.79 -2.63 -16 -20 -20 -15
Total Depreciation and Amortization (D&A)
0.18 0.17 0.11 0.09 0.10 0.10 0.11 0.12 0.13 0.13 0.13
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.12) ($0.10) ($0.11) ($0.10) ($0.11) ($0.12) ($0.11) ($0.09) ($0.08) ($0.07) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding
54.98M 55.02M 55.25M 54.98M 59.24M 59.24M 59.71M 62.39M 81.27M 87.09M 90.12M
Adjusted Diluted Earnings per Share
($0.12) ($0.10) ($0.11) ($0.10) ($0.11) ($0.12) ($0.11) ($0.09) ($0.08) ($0.07) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding
54.98M 55.02M 55.25M 54.98M 59.24M 59.24M 59.71M 62.39M 81.27M 87.09M 90.12M
Adjusted Basic & Diluted Earnings per Share
($0.12) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
52.20M 55.26M 59.23M 59.24M 59.24M 59.24M 72.95M 84.65M 86.24M 90.20M 90.20M
Normalized Net Operating Profit after Tax (NOPAT)
-4.36 -3.98 -4.42 -4.52 -4.59 -5.22 -4.71 -4.77 -4.77 -4.81 -5.27
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 58.34% 58.28% -0.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Vivani Medical (NASDAQ: VANI) remains a development-stage company with no reported revenue in the periods provided. Total revenue and gross profit were zero in every reported quarter, leaving the company dependent on cash reserves and equity financing to fund operations.

There are some signs of modest cost improvement. Second-quarter 2026 net loss narrowed to $6.37 million from $6.78 million in the first quarter and $7.14 million in the second quarter of 2025. Operating expenses were $6.87 million, down from $7.46 million a year earlier, primarily because selling, general and administrative expenses declined to $2.42 million and research and development expenses fell to $4.46 million.

  • Losses improved modestly year over year: Q2 2026 net loss of $6.37 million was smaller than the $7.14 million loss reported in Q2 2025.
  • Operating expenses remain below last year’s level: Total operating expenses declined approximately 8% year over year, with both SG&A and R&D expenses lower than in Q2 2025.
  • Liquidity is stronger than a year ago: Cash and equivalents totaled $19.89 million at June 30, 2026, compared with $6.79 million at June 30, 2025. Current assets of $21.64 million exceeded current liabilities of $6.66 million by a wide margin.
  • Liabilities declined during Q2: Total liabilities fell to $22.67 million from $23.27 million at the end of Q1 2026, while noncurrent liabilities declined by approximately $480,000.
  • Cash burn remains relatively consistent: Operating cash outflow was $6.04 million in Q2 2026, compared with $6.20 million in Q1 2026 and $6.09 million in Q2 2025. This suggests that quarterly spending has stabilized, but the company is still consuming substantial cash.
  • Other income provided some support: Vivani reported $504,000 of net other income in Q2 2026, reducing the impact of its operating loss. However, this income does not represent recurring product revenue.
  • Vivani has not yet established commercial revenue: Revenue has remained at zero throughout the supplied quarterly history, meaning future value depends heavily on successful development, regulatory progress and eventual commercialization of its products.
  • The company continues to rely on equity financing: Vivani raised $5.94 million through common-equity issuance in Q2 2026 after raising $9.82 million in Q1 and $20.70 million in Q4 2025. Financing provided nearly all of the quarter’s cash inflow and offset the company’s operating burn.
  • Share dilution is a significant risk: Weighted-average basic shares outstanding increased to 87.09 million in Q2 2026 from 81.27 million in Q1 2026 and 62.39 million in Q4 2025. Additional financing could further reduce existing shareholders’ ownership percentage.
  • The current cash balance may not support operations for long without additional funding: At a quarterly operating cash burn of roughly $6 million, the $19.89 million cash balance represents approximately three quarters of operating cash needs before considering changes in spending, financing or other uses of cash.

Overall, Vivani’s financial position is better than it was in mid-2025 because of substantial equity raises and a larger cash balance. Nevertheless, the company remains unprofitable, generates no revenue and funds its operations primarily through shareholder capital. Investors should focus on clinical or product-development milestones, the timing of potential commercialization and whether future financing can be completed without excessive dilution.

11/16/26 04:01 PM ETAI Generated. May Contain Errors.

Vivani Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Vivani Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Vivani Medical's net income appears to be on an upward trend, with a most recent value of -$26.61 million in 2025, falling from -$20.02 million in 2015. The previous period was -$23.49 million in 2024. View Vivani Medical's forecast to see where analysts expect Vivani Medical to go next.

Vivani Medical's total operating income in 2025 was -$27.56 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $27.56 million

Over the last 10 years, Vivani Medical's total revenue changed from $8.95 million in 2015 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, Vivani Medical's cash and equivalents has ranged from $2.63 million in Q3 2025 to $29.65 million in Q1 2024, and is currently $14.59 million as of their latest financial filing in Q3 2026.

Vivani Medical had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Vivani Medical's book value per share changed from 0.57 in 2015 to 0.22 in 2025, a change of -61.9%.



Financial statements for NASDAQ:VANI last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners